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Andrey Lisitsa
Institute of Biomedical Chemistry, Moscow, Russia
Proteomics is quite mature to assimilate new market
niches. These niches are created by natural curiosity of
proteome scientists, challenged by a number of difﬁculties
in developing actual deliverables for the market over 20
years of hard and enthusiastic work. Playing the proteomics
challenge without a team may be ﬁnancially risky. We have
launched new Flagship Programs of EuPA Initiatives in order
to help ﬁll the gap between the large and heterogeneous
European scientiﬁc community and the world of enterprises.
During the session we will discuss how the social networking
environment could be used to keep pace of investments in
proteomics. Representatives of future and current start-ups,
SMEs and large established corporations are invited for this
brainstorming.
http://dx.doi.org/10.1016/j.euprot.2015.07.002
Standardization initiative. Integrating
proteomic strengths across Europe
Fernando J. Corrales
Center for Applied Medical Investigation,
University of Navarra, Spain
Mass spectrometry has experienced huge advances in the
last decade increasing the accuracy and capacity of pro-
tein/peptide measurements in complex biological samples.
The possibility of massive protein identiﬁcation and quan-
tiﬁcation converts proteomics in one of the most valuable
analytical resources to understand sophisticated cellular pro-
cesses at the functional level. However, if proteomics has to
deliver its resources and capabilities to the scientiﬁc com-
munity then, reliability, robustness and reproducibility must
be ensured. To this end, it is mandatory to deﬁne quality
control procedures and standardized protocols for the whole
proteomics workﬂow, from sample collection and preparation
to data computational analysis and exchange. Noteworthy,
the translation of analytical results into relevant biological
knowledge and practical applications is often hampered by
the lack of standardized protocols that emerge, which, there-
fore, is an urgent need. To this end the initiative will focus
on the standardization of proteomics workﬂows to consoli-
date a common space integrating proteomic strengths across
Europe, to increase the penetrance of proteomics in other sci-
entiﬁc disciplines, to facilitate the implementation of state
of the art methods and technology in emergent platforms
and, very importantly, to generate synergies with industrial
partners.
http://dx.doi.org/10.1016/j.euprot.2015.07.003
Afﬁnity Binder Knock-Down Initiative
Tove Alm ∗, Emma Lundberg, Mathias Uhlén
Royal Institute of Technology (KTH), SciLifeLab,
Stockholm, Sweden
Background: An enormous amount of publicly available
afﬁnity binders are available on the market and many of the
afﬁnity binders are not working as expected. Several studies
suggest that only 25–50% of the antibodies meet the expec-
tations. This results in a lot of wasted resources (material,
time, and money). Therefore, a quality assurance program in
proteomics research is needed.
Purpose: The purpose of the Afﬁnity Binder Knock-Down
Initiative (‘Initiative’) is to gather knowledge in a systematic
and standardized system to assure the functionality of afﬁnity
reagents.
Implementation: The research community and life science
companies will jointly work on improved quality of afﬁn-
ity reagents. The participating industrial partners provide
antibodies and gene silencing reagents and the researchers
use gene silencing to prove antibody speciﬁcity in partic-
ular application(s). The results are submitted back to the
Initiative and made publicly available on Antibodypedia
(www.antibodypedia.com, a site for searching and comparing
antibodies). The researchers are reimbursed for the positive
data submitted. By joining this public-private partnership, the
participating parts agree to fulﬁll a number of undertakings
that will be discussed during the presentation.
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